Published in PLoS One on July 29, 2013
Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria (ARGISM) | NCT00616304
Decreased endothelial nitric oxide bioavailability, impaired microvascular function, and increased tissue oxygen consumption in children with falciparum malaria. J Infect Dis (2014) 2.10
Pathogenesis of cerebral malaria--inflammation and cytoadherence. Front Cell Infect Microbiol (2014) 1.06
Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood-brain barrier integrity? Fluids Barriers CNS (2014) 0.84
The evidence for a role of vasospasm in the pathogenesis of cerebral malaria. Malar J (2015) 0.82
Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections. MBio (2016) 0.81
Vascular dysfunction as a target for adjuvant therapy in cerebral malaria. Mem Inst Oswaldo Cruz (2014) 0.79
Pathophysiological Mechanisms in Gaseous Therapies for Severe Malaria. Infect Immun (2016) 0.79
Insert engineering and solubility screening improves recovery of virus-like particle subunits displaying hydrophobic epitopes. Protein Sci (2015) 0.78
Management of severe paediatric malaria in resource-limited settings. BMC Med (2015) 0.77
Endothelial-Leukocyte Interaction in Severe Malaria: Beyond the Brain. Mediators Inflamm (2015) 0.76
Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria. PLoS One (2017) 0.75
Decreased Rate of Plasma Arginine Appearance in Murine Malaria May Explain Hypoargininemia in Children With Cerebral Malaria. J Infect Dis (2016) 0.75
Severe malaria: what's new on the pathogenesis front? Int J Parasitol (2016) 0.75
Pharmacokinetic-Pharmacodynamic Model for the Effect of l-Arginine on Endothelial Function in Patients with Moderately Severe Falciparum Malaria. Antimicrob Agents Chemother (2015) 0.75
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet (2005) 12.98
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Arginine metabolism: nitric oxide and beyond. Biochem J (1998) 6.44
Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med (1993) 6.22
A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med (1996) 4.64
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol (1985) (2006) 3.07
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis (2008) 2.77
Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med (1996) 2.75
Malaria biology and disease pathogenesis: insights for new treatments. Nat Med (2013) 2.38
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet (2003) 1.86
L-arginine-induced hypotension. Lancet (1990) 1.77
Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog (2010) 1.37
Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis (2008) 1.26
Impaired skeletal muscle microvascular function and increased skeletal muscle oxygen consumption in severe falciparum malaria. J Infect Dis (2012) 1.15
Exogenous arginine in sepsis. Crit Care Med (2007) 1.07
EFFECT OF CATIONIC AMINO ACID INFUSION ON POTASSIUM METABOLISM IN VIVO. Am J Physiol (1964) 0.99
Pharmacokinetics of L-arginine in adults with moderately severe malaria. Antimicrob Agents Chemother (2008) 0.92
Safety profile of L-arginine infusion in moderately severe falciparum malaria. PLoS One (2008) 0.92
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 5.24
The pathophysiology of vivax malaria. Trends Parasitol (2009) 4.57
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis (2009) 4.00
Quantification of lean bodyweight. Clin Pharmacokinet (2005) 3.59
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis (2007) 3.02
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet (2002) 2.69
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med (2006) 2.65
A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J (2009) 2.64
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother (2002) 2.52
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J (2008) 2.41
Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop Med Int Health (2004) 2.36
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis (2012) 2.20
Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis (2011) 2.16
Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis (2009) 2.15
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis (2011) 2.11
What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol (2004) 2.01
Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol (2012) 1.95
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet (2003) 1.86
The anaemia of Plasmodium vivax malaria. Malar J (2012) 1.82
Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol (2008) 1.70
Inferred relatedness and heritability in malaria parasites. Proc Biol Sci (2010) 1.69
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malar J (2008) 1.69
Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax Malaria in Sabah, Malaysia. PLoS Negl Trop Dis (2013) 1.68
A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Clin Toxicol (Phila) (2011) 1.66
Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J (2013) 1.66
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis (2011) 1.64
Is plasma arginine concentration decreased in patients with sepsis? A systematic review and meta-analysis. Crit Care Med (2011) 1.63
Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J (2012) 1.61
Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol (2012) 1.59
Methanol and ethylene glycol acute poisonings - predictors of mortality. Clin Toxicol (Phila) (2011) 1.59
Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med (2007) 1.58
A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. Br J Clin Pharmacol (2014) 1.57
A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax (2010) 1.55
Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One (2011) 1.54
Plasmodium vivax trophozoites insensitive to chloroquine. Malar J (2008) 1.54
A simple score to predict the outcome of severe malaria in adults. Clin Infect Dis (2010) 1.54
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis (2006) 1.49
Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother (2004) 1.48
Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J (2012) 1.47
The global public health significance of Plasmodium vivax. Adv Parasitol (2012) 1.46
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46